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Abstract
Background: The current therapy of malignant gliomas is based on surgical resection, radio-chemotherapy and
chemotherapy. Recent retrospective case-series have highlighted the significance of the extent of resection as a prognostic
factor predicting the course of the disease. Complete resection in low-grade gliomas that show no MRI-enhanced images
are especially difficult. The aim in this study was to develop a robust, specific, new fluorescent probe for glioma cells that is
easy to apply to live tumor biopsies and could identify tumor cells from normal brain cells at all levels of magnification.
Methodology/Principal Findings: In this investigation we employed brightly fluorescent, photostable quantum dots (QDs)
to specifically target epidermal growth factor receptor (EGFR) that is upregulated in many gliomas. Living glioma and
normal cells or tissue biopsies were incubated with QDs coupled to EGF and/or monoclonal antibodies against EGFR for 30
minutes, washed and imaged. The data include results from cell-culture, animal model and ex vivo human tumor biopsies of
both low-grade and high-grade gliomas and show high probe specificity. Tumor cells could be visualized from the
macroscopic to single cell level with contrast ratios as high as 1000: 1 compared to normal brain tissue.
Conclusions/Significance: The ability of the targeted probes to clearly distinguish tumor cells in low-grade tumor biopsies,
where no enhanced MRI image was obtained, demonstrates the great potential of the method. We propose that future
application of specifically targeted fluorescent particles during surgery could allow intraoperative guidance for the removal
of residual tumor cells from the resection cavity and thus increase patient survival.
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Introduction
About 77% of primary malignant central nervous system (CNS)
tumors are classified as gliomas. In the USA about 18,000 cases of
glioma are diagnosed every year and about 13,000 patients die of
this disease annually[1]. Following the definition of the world
health organization (WHO) gliomas are classified by their
aggressiveness in grades from I to IV [2]. The more aggressive
grades (III and IV) are also termed high-grade gliomas, whereas
grade II tumors are termed low-grade. The pilocytic astrocytoma
of the young adult and children is the only glioma WHO grade I
(benign). Despite advances in surgical procedures and adjuvant
therapies, the prognosis of malignant brain tumors remains poor.
Gross surgical resection of high-grade gliomas has been demon-
strated in prospective controlled trials to extend the survival of
glioma patients significantly [3,4,5] (evidence level I). No level I
evidence exists for low-grade gliomas. However, recent studies
(retrospective case-series, evidence level V) favor early surgery and
support a radical removal of diffuse low-grade gliomas if
achievable at an adequate risk level [3,4]. Most recurrent high-
and low-grade gliomas arise from the primary site of the glioma or
within the directly adjacent brain tissue. The longer survival time
after more complete resection as well as the frequent recurrence in
the area of the primary site suggest that the recurrent gliomas arise
from remaining primary tumor cells in or close to the wall of the
resection cavity.
Application during surgery of 5-aminolevulinic acid (5-ALA),
which is metabolized to fluorescent protoporphyrin IX, was shown
to increase ’’total resections’’ from 36% to 65% as defined by loss
of post-operative MRI contrast-enhancing tissue [6]. However,
doubts persist as to the efficacy of the identification and resection
of microscopical tumor remnants in the penumbra of the dye, in as
much as the fluorescent agent is not restricted to the tumor cells
but is found in the intracellular space where it can freely diffuse
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11323[7]. Furthermore 5-ALA does not stain low-grade gliomas, which
are even more difficult to discriminate from the surrounding brain
tissue because of the smaller change in cell morphology and the
lack of MRI contrast.
Genome-wide profiling of archival glioma samples have
revealed that Her1 (epidermal growth factor receptor, EGFR)
expression and/or gene dosage is upregulated in .40% of all
gliomas and ,90% of WHO grade IV glioblastoma multiforme
tumors (GBM)s [8,9,10,11] as well as low grade oligodendroglial
tumors [12] compared to normal adult brain. Cell biological
experiments have shown that EGFR can be specifically labeled on
live cells with fluorescent nanoparticles, semiconductor quantum
dots (QD) [13,14]. In this report we demonstrate that QDs
specifically targeted to EGFR, can clearly distinguish low-grade as
well as high-grade glioma tissue from normal brain tissue both at
the macroscopic and the single cell level with very high contrast
ratios in ex vivo experiments. The strong, photostable fluorescence
and rapid differential binding of these probes meet some of the
criteria required by surgeons to distinguish tumor cells left in the
resection cavity.
Results
Kinetics of binding of QD-EGF in cultured glioma cells
and alternative staining with MAbs and QD-GAMIG
QD-EGF (mono-biotinylated EGF coupled to Streptavidin-
(PEG)- QDs, Invitrogen) was applied to cultured human glioma
cell-lines in monolayer culture at 37uC. QDs lacking conjugated
EGF were not taken up by any of the cell lines. The kinetics and
extent of uptake was quantitated for G-28 and U87 cell lines by
flow cytometry (Fig. 1A). Extensive uptake was achieved in less
than 30 minutes. Staining of three-dimensional spheroids derived
from G-28 and U87 cells maintained in non-adherent tissue
culture conditions resulted in penetration and uptake of QD-EGF
at least 2 or 3 cell layers into the spheres (data not shown). In a
survey of 15 established human glioma tissue cell lines we observed
that binding of QD-EGF varied considerably, consistent with the
known variability of wildtype and mutant EGFR expression in
gliomas. The EGFR mutant vIII lacks the EGF binding site but is
constituitively active and is expressed in ,60% of high-grade
gliomas EGFR [15]. Such tumors will not bind QD-EGF but
should be targeted by antibodies against the ectordomains of
EGFR. We tested lines expressing EGFR with three different
monoclonal antibodies (MAb) directed against various epitopes in
the ectodomain of the EGFR (528, H-11, and 199.12) and QD-
coupled secondary antibodies. A comparison of staining for the
lines G-28, U87 and G-112 using the two procedures is shown in
Figure 1B,C. Note that the image of the G-112 line stained with
QD-EGF was acquired at 10x the laser power as the images for
lines G-28 or U87 (Fig. 1B) whereas all imaging conditions were
identical for QD-MAb staining (Fig. 1C). Fixed cell lines were also
tested by normal immunofluorescence staining for EGFR
expression with antibodies directed against either the extracellular
or the cytoplasmic domain of the receptor as well as by cell lysis
and western blot analysis (see Supplementary Figure S1). QDs
without EGF or anti-EGFR Mab coupling did not bind to the cell
lines nor did QDs coupled with isotypic but unrelated antibodies
such as to Her2 or CMV.
QD-EGF and QD-MAb staining in the orthotopic glioma
model
G-28 and U87 experimental glioma bearing mouse brains were
explanted and coronary sections were stained immediately at
37uC. White light illumination of the explanted mouse brains
showed a distorted anatomy, a loss of normal white and gray
matter structures of normal mouse brain, and increased tissue
volume at the site of the tumor implantation. Samples from tumor
tissue and from the nonimplanted contralateral hemisphere were
stained with QD-EGF for the G-28 tumors and monoclonal
antibody coupled QDs (QD-MAb H199.12) for the U87
implanted mice, respectively. Tissue samples were examined by
confocal microscopy. As in the cell cultures, G-28 cell line derived
tumors in mouse brain showed extensive uptake of QD-EGF
(Fig. 2A,D) and no uptake of untargeted QDs. Three-dimensional
data stacks demonstrated a penetration of QD-EGF to about 20-
30 mm into the tumor tissue slices. Tissue from the uninjected
brain hemispheres stained with the targeted QD probes did not
bind these or untargeted probes as shown in Figure 2B,E. After
fluorescence imaging, all samples were forwarded for histo-
pathological examination. Conventional H&E (haematoxylin and
eosin) staining of sections from the QD imaged tissue (not
necessarily corresponding to the same areas imaged) demonstrated
the presence of solid and highly cellular tumor tissue in the
samples positive for specific QD-fluorescence, whereas no tumor
was detected within the contralateral hemisphere (Fig. 2C,F).
Similar results were obtained with the U87 cell-line derived
gliomas using QD-MAb199.12 (Supplementary Movie S1).
QD-EGF and QD-MAb staining of human glioma biopsies
Human brain tumor biopsies were taken during standard
neurosurgical resection of two glioblastoma multiforme WHO
grade IV (GBM), one anaplastic astrocytoma WHO grade III and
one oligodendroglioma WHO grade II. The high-grade tumors
were located such that presumably unaffected, brain tissue had to
be explanted during the surgical access (partial temporal
lobectomy), providing control brain tissue for the staining under
identical conditions with targeted QD probes as the tumor tissue.
Both tumor tissue and normal brain tissue were also stained with
control QDs lacking the EGF or primary antibody conjugation or
conjugated to non-expressed epitopes and showed no binding. In
the cases of the low-grade tumors where no normal brain tissue
was resected, the tumor tissue was stained with non-targeted,
streptavidin-(PEG)-QDs and goat-anti-mouse IgG coupled QDs
for control. The biopsy sites of one of the GBM cases are
illustrated on the preoperative gadolinium enhanced MRI scans in
Figure 3A and for the second GBM see Supplementary Figure
S2A (the arrow indicates the MRI positive tumor mass and the
arrowhead, the adjacent brain tissue). The tissue specimens were
placed on ice for a short period to transport the samples from the
operating room to the laboratory before staining at 37uC. Samples
of tumor tissue and brain were incubated with QD-EGF, as well as
MAb QD-528, QD-H11, and QD-H199.12 at 37uC. In the case
of both GBMs, areas of solid tumor and relatively unaffected
adjacent brain tissue were easily distinguished macroscopically by
visual observation after staining or with a normal digital
photographic camera under UV Hg-halide light illumination
(Fig. 3B,C (tumor) compared to D (adjacent brain); Suppl. Fig.
S2B compared to C). H &E staining of the respective tissues (e.g.
Suppl Fig. S2D and E) confirmed the identities of the tumor and
normal tissues. Staining the biopsied (macroscopically) supposedly
tumor-free tissues at the edge of the resection cavity with QD-
MAb528 EGFR revealed the presence of remaining tumor cells
not detected at the resolution of the enhanced MRI image in one
of these tissue specimens as shown in Figure 3E (compare to 3D)
and confirmed by post processing H&E staining.
Both GBM QD-stained biopsies were imaged in a confocal
scanning Zeiss 510 Meta microscope and a high-speed Program-
mable Array optical sectioning (PAM) microscope at higher
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microscope using patterned illumination and detection that
achieves high-speed, single-molecule sensitive imaging
[16,17,18]. Specific uptake of QD-EGF in individual tumor cells
could be discerned at increasing magnifications (10X, 20X, and
40X) as shown for a single tissue specimen (Fig. 4). In the case of
GBM X some of the tumor tissue was necrotic, showing distorted
nuclei and no uptake of QD-EGF although it was positively
stained by QD-MAbEGFR (Figs. 5 and 6). PAM images of QD-
EGF probed tissues were used to quantitate the very high specific
QD-fluorescence in the tumor compared with the adjacent brain
samples which showed no specific uptake (see for example Suppl.
Fig. S5A, tumor, compared to S5C, adjacent brain). The
fluorescence intensities in the QD emission (635–675 nm) channel
were .10
3 times higher for the tumor tissue than those recorded
from the normal brain tissue. Similar results were obtained by
staining with the three QD-MAbs with contrast ratios between 200
and 1000 between tumor and brain biopsy tissues using the same
probes on the two different tissues. Extensive imaging was
performed on tissue stained with QD-EGF, QD-MAb-528 and
QD-MAb-H199.12, Figs. 3,4,5,6; Supplementary Movies S2, S3,
S4; and Supplementary Figs. S3, S4, S5 for both tumors.
Figure 1. Specific targeting of EGFR on glioma cell lines by QDs. (A) Flow cytometric analysis of uptake of 655QD-EGF by cell line G28 (upper
panel), and U87 (middle panel) at 37uC. Histograms for the time points 0, 5, 15, 35 and 60 min are displayed on a log scale. Excitation, 488 nm,
emission 635–675 nm. Lower panel, mean intensity values for the various time points. Non-targeted QD staining of the cells gave the same
fluorescence values as the unstained cells and are plotted as the 0 time point. Confocal fluorescence and phase images of monolayer cells after
staining with (B) 2 nM 655QD-EGF or (C) MAb H199.12 antibody and 625QD-goat anti-mouse F(ab)2. Zeiss 510 Meta CLSM imaging. Excitation
488 nm, emission 615–700 nm and 595–680, B and C respectively, with a 40X water immersion, NA 1.2 objective. Fluorescence images of QD-EGF (A)
on G28 and U87 cells lines were acquired with the same sensitivity and G-112 with a 10-fold higher laser intensity, whereas images in (C) were
acquired at 595–680 nm with only a 4-fold difference in sensitivity for G-112. The images are maximum intensity projections of 0.5 mm optical
sections after background substraction and median filtering. Bar, 20 mm.
doi:10.1371/journal.pone.0011323.g001
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tumor tissue had a much higher density of nuclei than the tissue
from the non-gadolinium positive region of both GBMs (e. g.
Suppl. Fig. S5B,D).
All samples were processed for conventional histo-pathological
examination after completion of the fluorescence imaging studies.
Histology confirmed elements of a glioblastoma WHO grade IV in
specimens that showed specific QD fluorescence, whereas the
tumor-adjacent brain samples contained predominantly grey and
white matter (Suppl. Fig. S2C and E). Results from both high-
grade GBMs were similar and supported the hypothesis that QDs
targeted to EGFR can specifically recognize glioma cells ex vivo.
Figure 2. QD-EGF staining of an orthotopic mouse brain tumor. (A,B) Tissue sections from control contralateral hemisphere of a mouse
injected with G28 human glioma cells and stained with 625QD-EGF. (D,E) Tumor tissue from the injected hemisphere. (A,D) Maximum intensity
projections of 25 confocal optical sections at 1 mm intervals of the intensities 595-659 nm; (B.E), 530/20 nm (autofluorescence), Zeiss Meta CLSM,
excitation 488 nm, 2060.5 NA objective. Tissue imaged in panels A and B were treated identically to that in panels D and E and thereby constitute
controls for the specificity of staining. (C,F) H & E staining and sectioning of tissue from the same hemispheres for pathology. Data were acquired with
the same sensitivity and are not contrast stretched; some pixels in image D are saturated. Bar is 20 mm.
doi:10.1371/journal.pone.0011323.g002
Figure 3. MRI and QD-probe digital macroimages from glioblastoma multiforme, grade IV biopsy X. (A) T1 weighted MRI axial scan
showing gadolinium positive signal. (B–E) Digital macrophotographic images of ex vivo stained biopsies from the resected tumor and adjacent brain
tissue stained with targeted QD probes taken with the same magnification and the same exposure times. Tumor tissue (B) 625QDStAv-biotin-MAb528
EGFR staining, (C) 625QDGAMIG-MAb 199.12 EGFR staining. Adjacent brain, (D) 625QDStAv-biotin-MAb528 EGFR staining, (E) invading tumor tissue,
625QDStAv-biotin-MAb528 EGFR staining. Excitation, 365 nm; emission .450 mm. Objective 5X NA 0.15. Bar 1 mm. Note that panel D serves as the
control for panel B, ie stained with the same probes under identical conditions.
doi:10.1371/journal.pone.0011323.g003
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delineate low-grade gliomas where no discrete boundaries are
visible in MRI scans and no uptake of 5-ALA occurs. Therefore, we
applied similar probes as those described above to grade II and
grade III biopsy tissue. The first sample described was an anaplastic
astrocytoma WHO grade II/III which showed no MRI galodinium
contrast enhancement but only evidence of inflammation (Fig. 7A
T1 and 7B FLAIR). The macro pictures of the stained tissue
sections are seen in panels C-F. A control from the surrounding
brain tissue could not be obtained in this case, because the
superficial situation of the tumor did not require resection of
adjacent brain. Tumor tissue was used as control and stained with
non-targeted QDs (Fig. 7F). By microscopic examination of QD-
EGFR targeted tumor, stained cells could be discerned scattered
throughout autofluorescent tissue more closely resembling normal
brain tissue (Fig. 7C). The high nuclear density and QD-MAb
EGFR staining are shown in a reconstruction of 11 optical sections
taken on the PAM (22 mm depth) in Figure 8, and another sample
on the CLSM of a 24 mm depth reconstruction, Supplementary
Movie S5. The neuropathological examination revealed scattered
mitoses as signs of malignant transformation from WHO grade II to
III throughout the biopsy. (5-ALA was not applied in this surgery).
A further case examined by QD-bioconjugate targeted staining
was a low-grade glioma with no MRI contrast enhancement
(oligodendroglioma WHO grade II) Figure 9A. Again no
surrounding brain tissue could be resected during surgery. However
staining with QD-MAb-EGFR resulted in a 200-fold elevated tissue
fluorescence (Fig. 9B,C), quantitated at higher magnification (see
Fig. 10), compared to the autofluorescence or staining with
uncoupled QD as control (Fig. 9E). The tumor tissue was also
weakly positive for targeted QD-MAb-PDGFa (Fig. 9D, Suppl. Fig.
S6); PDGFa being a cell surface marker that has been linked to
oligodendroglioma tissue [12,19,20]. Strong staining by QD-
MAb528 EGFR was seen throughout the entire 250 mm thickness
of the small biopsy tissue (Fig. 9C) Figure 10, Supplementary Movie
S6.A high nucleardensity wasseen inall oftheQD positiveareas as
shown in Supplementary Figure S7A. Although some of the biopsy
tissue could be stained throughout (Fig. 10) in many cases as stated
previously the QD targeted probes can only penetrate about 3 cell
layers due to the density of the tumor tissue and the size of the QDs.
Thisisshown bya 3-Dvolumeprojectionreconstruction(Suppl.Fig
S7B)ofthefluorescentimage planes inwhichonecanseeQD-Mab-
EGFR fluorescence extending to 26 mm (3 cell layers) and nuclei
visible to 36 mm (an additional 1–2 cell layers). Individual tumor
cells are clearly distinguishable at this magnification as seen by
nuclei demarcated by surrounding QD-probe staining.
These data show conclusively that glioma tumor cells even in
low-grade tumor biopsies expressing EGFR can be visualized at
both macroscopic and microscopic magnifications by specifically
staining with monoclonal antibodies against EGFR and/or EGF,
and in some cases to monoclonal antibodies against PDGFR,
coupled to quantum dots.
Discussion
QD and EGFR
QDs have unique advantages for cellular imaging [21]: (i) high
absorption cross-sections and quantum yields, permitting detection
down to the single nanoparticle level and reliable quantitative
detection of binding and transport phenomena; (ii) extreme
photostability, allowing imaging over prolonged periods; (iii) broad
excitation spectra rising toward the UV, allowing the simultaneous
excitation of different QDs; and (iv) narrow, tunable emission bands
throughout the visible spectrum. QDs with the proper bioconjuga-
tion are not taken up non-specifically by cells but can be easily
coupled to biomolecules targeting specific receptors, as some of us
have demonstrated using living cultured cells [13,22,23].
The obvious marker for our QD probe was the epidermal
growth factor receptor (EGFR or Her1), upregulated in many
head and neck tumors and an established target for glioma
Figure 4. Three magnifications of a tissue specimen from human GBM Y stained with QD-MAb-EGFR. Maximum intensity projections of
PAM acquired conjugate (confocal) images stained with 655QDGAMIG-MAb 199.12 EGFR. (A) 36 1-mm optical sections, 10X NA 0.3 objective; (B) 26 1-
mm optical sections, 20X NA 0.5 objective; (C) 18 1- mm optical sections, 40 X NA 0.75 objective. Excitation 488 nm, emission 655/40 nm. Boxes denote
the area enlarged in the next corresponding image. Bar 20 mm. Control for the staining shown in this figure is seen in Supplementary Fig. S2, panel C.
doi:10.1371/journal.pone.0011323.g004
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important in the embryogenesis and development of the central
nervous system. With the completion of the growth processes of
the brain in adulthood the EGFR is down regulated. However,
EGFR is involved in the tumorgenesis of gliomas [9,24,25,26,27].
The data presented here show highly specific labeling of native
human glioma biopsies that can be distinguished from normal
brain tissue down to the single cell level by staining with QD-EGF
and/or QD-MAb anti-EGFR. The ability of the QD-conjugate to
identify low-grade glioma biopsies constitutes to our knowledge the
first specific ex vivo staining of low grade-glioma cells in tissue. The
delineation of the tumor cells was apparent at all microscopy
magnifications.
A survey of 15 human glioma cell lines showed that MAbs
against the ectodomain of EGFR could positively identify lines
that were negative for EGF binding due to mutations in the EGF
binding site or lines with low receptor density. The cell line G-112
is one such line that bound Mab against EGFR but very weakly
bound QD-EGF Fig. 1B,C and Suppl. Fig S1. In view of the
upregulated Her1 (epidermal growth factor receptor) expression
and/or gene dosage in .40% of all gliomas [9,24,25,26,28,29,30]
as well as in low grade oligodendroglial tumors [12], we postulate
that a cocktail of QDs attached to several MAbs against EGFR as
well as QD-EGF would unambiguously distinguish these gliomas
from normal human brain. Other possible cell membrane epitopes
that are upregulated on glioma cells compared to normal brain
tissue are PDGFRa [20,30]and several integrins [31] which could
also be considered for an even more general cocktail. In particular,
low grade gliomas express a variety of glial progenitor markers
concomitant with PDGFRa [20,30].
Although the uptake of QDs and retention in animals has not led
to adverse effects over periods of months [32,33], there remain
concerns about the toxicity of the core (CdSe) of semi-conductor
QDs should the particles breakdown intracellularly. We expect that
less- or non-toxic yet equally fluorescent nanoparticles based on Si
[34], noble metals or dendrimers with long wavelength emission but
benign chemical compositions will become commercially available.
Chemical coupling of biomolecules to QDs and such particles can
be effected without using streptavidin-biotinconjugates such that no
antigenicity would be provoked by their use.
The PAM high-speed sectioning microscope is presently a
research laboratory prototype. Newer designs that could be
directly applicable to the surgical theater and provide single cell
sensitivity are under development within an EU-funded project
(http:www.mpibpc.mpg.de/fluoromag) and are expected to be
ready for commercialization in the near future.
Future prospects
This study has been restricted to glioma cell lines, mouse
orthotropic tumors and ex vivo human biopsy material. The results
Figure 5. Staining of GBM X with EGFR targted QDs. (A,B) Maximum intensity projection of 19 2-mm confocal sections through the tumor tissue
stained with 625QDStAv-biotin-MAb528 EGFR, excitation 488. A QD emission 595–649, B autofluorescence emission 520–553. Field in panels A & B,
230 mm, bar 50 mm. Controls for these probes are shown in Fig. 3, panel D. C tumor tissue stained with 625QDGAMIG-MAb 199.12 EGFR,
counterstained with DRAQ5 for DNA. Excitation 488, QD emission 595–649, red; autofluorescence 520–552, green. DRAQ5 excitation 633, emission
660–745 nm, blue. D tumor tissue stained with 625QDStAv-biotin-EGF, counterstained with DRAQ5. Excitation and emission wavelengths and size as
in C. Field in panels C & D, 153 mm, bar 25 mm. Objective 20X NA 0.5.
doi:10.1371/journal.pone.0011323.g005
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normal brain both in high-grade and low-grade biopsies. Presently
there are no specific markers available to surgeons for directing
resection of low-grade tumors. We anticipate in the future that
targeted fluorescent nanoparticles will find use in directing resection
guidance for low-grade glioma tumors similarly as 59ALAstaining is
used in high-grade glioma resections presently.
While this paper was under review Nyugen et al. published a
study in which fluorescent particles with sites for MMP2 enzyme
cleavage were used for labeling orthotopic mammary tumors in
mice for improved surgical resection[35]. While MMP2 is
frequently upregulated in tumors it is also present in normal
tissue and the differential staining achieved in this study was a
maximum of 13.6-fold.
The use of highly fluorescent-nanoparticle conjugates for
identification of brain tumor cells could be extended to targeting
molecules for specific histotyping of brain tumors, as demonstrated
for the PDGFa-receptor in the oligodendroglioma sample. It may
even be possible to analyze the functional states of tumor tissue
with such reagents. Stem-cell markers have identified a subpop-
ulation of glioma cells that show aggressive tumor growth
associated with a poor prognosis [20,36]. Identification of
specifically aggressive clusters of cells would allow their selective
removal. In summary, we foresee the emergence of new, smart
nanoparticles for gene expression-dependent resection guidance.
Materials and Methods
Cell culture and orthotopic glioma mouse model
The human glioblastoma derived cell lines G-112, G-28 [37,38]
and U87 (source, ATCC) were grown in MEM containing 10%
FCS. All cell lines were free from mycoplasma. For intracranial
implantation in nude NMRI mice, cells were harvested from
monolayer culture by trypsin digestion. Cells were washed and
resuspended at a concentration of 2610
4/ml. Prior to the
implantations, animals were anaesthetized by peritoneal injection
of ketamine/xylazine solution (200 mg ketamine and 20 mg
xylazine in 17 ml of saline) at 0.15 mg/10 g of body weight. For
the procedure the cranium was fixed in a stereotactic frame (TSE
Systems, Bad Homburg, Germany). A 1 mm burr hole was placed
3 mm lateral to the bregma and a stereotactic implantation of 3 ml
cell suspension injected over 3 min was placed in an area
corresponding to the internal capsule 0.5 mm below the tracts of
the corpus callosum. Following implantation, 50 mg/kg novamin-
sulfone was administered s.c. and 1 mg/ml novaminsulfone was
added to the drinking water for three days to relieve postoperative
pain. Four weeks post implantation, tumor-bearing brains were
explanted following a lethal intraperitoneal injection of 50 mg/kg
xylazine and 350 mg/kg ketamine. Coronal sections of the mouse
brains were performed immediately and the sections were
processed for EGFR-QD staining. Animal studies were approved
by the animal study referee of the Georg-August-University in
Go ¨ttingen and the animal research commission of Germany in
Braunschweig.
Human tumor biopsies and histologies
The ethical committee of the Georg-Ausgust University,
Go ¨ttingen, gave permission for staining of glioma tissue removed
during standard neurosurgical procedures in conjuction with our
optical tissue analysis project. Informed written consent was given
by all patients included in this study. The human biopsies were
taken during standard neurosurgical procedures. Biopsy sites were
in the central tumor mass and, where possible, in tumor adjacent
brain as defined by image guided neuronavigation. They were
registered by neuronavigation and correlated to the preoperative
MRI-scans (3T, Magnetom Trio, Siemens Medical Solutions,
Erlangen, Germany). Human brain tumor biopsies were imme-
diately processed for EGFR targeted QD-staining. Following the
imaging studies all specimens were formalin fixed and the tissue
blocks were sectioned parallel to the optical imaging plane. The
tissue blocks were paraffin embedded and 5 mm sections were cut.
Standard H&E staining was performed. All samples were graded
by a neuropathologist.
QD coupling with EGF and monoclonal antibodies
Mouse monoclonal antibodies (MAb) 528 (IgG2a), H-11 (IgG1)
and H199.12 (IgG2a), specific for the extracellular portion of
human EGFR (Her1), were obtained from Dianova or purified
from monoclonal cell culture supernatant by Protein G Sepharose
chromatography. H-11 and H199.12 recognize both wt EGFR
and EGFRvIII. Mouse monoclonal antibody CD140a (biotiny-
lated anti- PDGFRa (IgG1) was purchased from BioLegend. QD-
EGF ligand was formed by incubation of biotin-EGF (Molecular
Probes) with 20 nM streptavidin conjugated, pegylated
655QDStAv (Q10121MP), 625QDStAv (A10196), or 705QDStAv
(Q10161MP) (Invitrogen) at a 3:1 ratio at 4uC with mixing for
.30 min in PBS with 0.5% BSA. MAbs were either directly
conjugated to amino-QDs (Invitrogen) or QDStAv (for biotiny-
lated 528 and PDGFRa) or staining was carried out in 2 steps
using MAb followed by QD-coupled goat anti-mouse (Fab)2
(GAMIG) (Q11021MP or A10195) (invitrogen). The peak
emission wavelength of the QDs is denoted throughout the text.
Staining of cell cultures and tissue samples
Glioma cell lines were plated on glass coverslips or in coverglass
chamber slides (Lab-Tek, Nunc) and stained in vivo for 30 min at
Figure 6. Staining of invading tumor cells in GBM X with EGFR
targted QDs. Maximum intensity projection of 40 confocal 2-mm
optical sections through tissue adjacent to tumor area with presumed
invading tumor tissue (tissue as shown in Figure 3E) stained with
625QDStAv-biotin-MAb528 EGFR, excitation 488. QD emission 595-649,
autofluorescence emission 520-553. Objective 20X, NA 0.5. Field
460 mm, Z depth 80 mm, bar 100 mm.
doi:10.1371/journal.pone.0011323.g006
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cellular portion of Her1 followed by either conventional
fluorophore labeled GAMIG or QD-coupled GAMIG. Imaging
was performed on the live cells or after fixation in 3.7%
paraformaldehyde (results were the same for either condition).
For kinetic studies on the rate and extent of QD-EGF uptake, cells
were incubated for the times specified in the text, harvested by
trypsin, fixed in paraformaldehyde and analyzed by flow
cytometry. Both unlabeled cells and cells incubated with QDs
without EGF gave the same peak shown as the zero time point.
Tissue slices obtained from animal models or surgical biopsies
were stained ex vivo in Tyrode’s buffer containing 1% BSA at 37uC
containing 4 nm QD-EGF or QD-MAb for 30 min with gentle
agitation followed by 3 changes of Tyrode’s/BSA for 15 min or
30 min of 10 mg/ml MAb followed by washing and subsequent
staining with 10 nM QD-GAMIG and washing. The scheme for
ex vivo staining is shown Supplementary Fig. S8. Tissue slices were
either imaged directly or fixed in 3.7% paraformaldehyde for
24 hrs and kept in PBS in 4-well Lab-Tek coverglass chamber
slides for macro and microscopic imaging. (A preliminary report of
Figure 7. MRI and QD-probe digital macroimages from an astrocytoma III. (A) T1 weighted MRI axial scan with no gadolinium positive
signal. (B) FLAIR MRI of the same section as in a. (C–F) Digital macrophotographic images of ex vivo stained biopsies from the resected tumor stained
with targeted (C–E) QD probes or untargeted QDs taken with the same magnification and the same exposure times. (C) 625QDStAv-biotin-MAb528
EGFR staining. (D) 625QDStAv-biotin-EGF staining. (E) tumor margin 625QDStAv-biotin-MAb528 staining. (F) uncoupled 625QDStAv staining.
Excitation, 365 nm; emission .450 mm. Objective 5X NA 0.15. Bar 1 mm.
doi:10.1371/journal.pone.0011323.g007
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SPIE International BIOS conference, January 24, 2009 [39]).
Macroscopic observation
Tissue sections were excited by epi-illumination with an X-Cite
Hg-halide lamp (EXFO, Mississauga, Ontario) at 365 nm through
a 10X NA 0.3 objective of an Olympus IX71 inverted fluorescence
microscope and observed with a 410 nm or 510 nm longpass
emission filter on a Canon EOS 40D camera attached to the
camera port of the microscope. Photographs were also taken from
above the sample, with a Canon EOS 40D camera with a zoom
EF 70–200 mm f/4 L IS, EF 1.4x II extender and 500 D close-up
lens.
Confocal laser scanning microscopy
A Zeiss CLSM 510 Meta microscope was used for imaging
immunofluorescent and QD labeled cell lines and tissue sections.
Laser excitation wavelengths were 488 nm for QD fluorescence,
532 nm for Cy3 and 633 nm for Cy5. Cell monolayers were
imaged with a 40X NA 1.2 water immersion objective. QD
labeled tissue sections were imaged with a 10 X NA 0.3 dry
objective. In tissue labeled with QD 625, DNA was stained after
fixation with 5 mM DRAQ5 (Biostatus Ltd, Leicestershire, UK)
and imaged with HeNe laser excitation at 633 nm, emission
.6501 nm.
PAM, high speed sectioning microscopy
A Programmable Array Microscope [18] (PAM) prototype
widefield optical sectioning microscope was used for sensitive high
speed imaging of QD-targeted tissue slices. The PAM uses a
ferroelectric liquid-crystal-on-silicon (LCoS, Fourth Dimension
Displays, Dumferline, Scotland) reflective array to create struc-
tured patterns for excitation and emission. Both conjugate
(emission largely from the focal plane) and non-conjugate (largely
out of focus emission) images were acquired by an iXon DV885
emCCD camera (Andor, Belfast, Ireland) on an Olympus IX71
inverted microscope equipped with Prior XY and piezoelectric
Nano Z stages using 10X NA 0.3, 20X NA 0.5, or 40X NA 0.75
Figure 8. QD-EGFR targeted staining of astrocytoma biopsy.
PAM sectioned maximum projection image of 11 slices at 2 mm
intervals. 625QD-biotin-MAb528EGFR excitation 488 nm, emission 625/
40 nm and DRAQ5 excitation 658 nm, emission 700/40 nm overlay. Bar,
25 mm. Control staining is shown in Fig. 7, panel E.
doi:10.1371/journal.pone.0011323.g008
Figure 9. MRI and QD-probe digital macroimages from an oligodendroma stage II. (A) T1 weighted MRI axial scan with no gadolinium
positive signal. (B–E) Digital macrophotographic images of ex vivo stained biopsies from the resected tumor stained with targeted (B–D) QD probes
or untargeted QDs taken with the same magnification and the same exposure times. (B,C) 655QDStAv-biotin-MAb528 staining. (D) 655QDStAv-biotin-
PDGFRa staining. (E) uncoupled 655QDStAv staining. Excitation, 365 nm; emission .510 mm. Objective 5x, NA 0.15. Bar 1 mm.
doi:10.1371/journal.pone.0011323.g009
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the combined conjugate and non-conjugate images. Excitation
was with an argon ion laser at 488 nm and emission collected with
624/40, 655/40 nm or 705/40 nm (Chroma, Rockingham,
Vermont) bandpass emission filters. DNA-DAPI images were
recorded without sectioning using 365 nm excitation from a Hg/
halide Exfo lamp and 450/40 nm emission. DNA-DRAQ5 images
were obtained by HeNe laser excitation at 658 nm with emission
at 705/40 nm.
Flow cytometry
The cells stained for determination of the kinetic uptake of 655
QD-EGF were measured in a Coulter Epics Flow Cytometer with
488 nm argon ion laser excitation, emission at 655/40 using
logarithmic PMT settings. The histograms represent 50,000 cells
per time point with all cells measured at the same gain settings.
Supporting Information
Figure S1 Western blot for EGFR expression of glioma cell lines
shown in Figure 1 compared to Hela cells. EGFR was quantitated
with rabbit polyclonal antibody 1005 (Santa Cruz Biotech) and
tubulin with Mab 21D3 (gift from Mary Osborne) after HRP-
secondary antibody binding and ECL (Pierce). G28 expresses
53%, U87 expresses 60% as many receptors as Hela and G-112,
5% as many.
Found at: doi:10.1371/journal.pone.0011323.s001 (0.38 MB TIF)
Figure S2 Human glioblastoma multiforme, grade IV biopsy, Y.
(A) Biopsy sites are denoted on the preoperative gadolinium
enhanced MRI scan. The arrow denotes biopsy region in tumor
tissue, arrowhead in adjacent brain. Digital macrophotographic
images of the 655QD-EGF stained (B) tumor tissue, (C) brain
tissue adjacent to the tumor site. Excitation, 365 nm; emission
.450 mm. Objective 5X NA 0.15. Bar 1 mm. (D,E) Sectioned
and H&E stained images of the same respective tissue specimens
after fixation and embedding for pathology. Bar, 4 mm.
Found at: doi:10.1371/journal.pone.0011323.s002 (1.20 MB TIF)
Figure S3 PAM image of QD-anti-EGFR staining of GBM Y.
Biopsy stained with MAb 199.12 and 655QD-GAMIG. Maxi-
mum intensity project of 27 1-mm optical sections of tissue from
GBM shown in Fig. 3d, some pixels are saturated. PAM image,
20X 0.5 NA objective, excitation 488 nm, emission 655/40 nm.
Bar, 25 mm.
Found at: doi:10.1371/journal.pone.0011323.s003 (1.03 MB TIF)
Figure S4 Stereopair of GBM Y staining by QD-EGF.
Maximum intensity projection of 11 5-mm confocal optical
sections (XY, 921 mm; Z depth, 55 mm) of tumor tissue stained
with 655QDStAv-biotin-EGF. Excitation 488 nm, emission
.650. Objective 10X, NA 0.3. Bar, 100 mm.
Found at: doi:10.1371/journal.pone.0011323.s004 (2.24 MB TIF)
Figure S5 PAM images of anti-EGFR stained GBM Y biopsy
and adjacent human brain tissue specimens. Human biopsy of a
GBM and adjacent brain tissue stained with 655QDGAMIG-
MAb 528 EGFR. (A) PAM images from the galodinium positive
area and (C) from adjacent brain tissue; (B,D) widefield DAPI
staining of nuclei in the surface cells of the same areas as shown in
A and C respectively. (A) Maximum intensity projection of 23 1-
mm optical sections of the QD-targeted tumor specimen. (C)
Maximum intensity projection of 35 one mm sections of QD-
targeted adjacent brain tissue. PAM images, 20X 0.5 NA
objective, excitation 488 nm, emission 655/40 nm. Bar, 20 mm.
Found at: doi:10.1371/journal.pone.0011323.s005 (0.97 MB TIF)
Figure S6 QD-anti-PDGFR targeted oligodendroma tissue.
Maximum intensity projection of PAM images from 50 sections
at 2 mm intervals through oligodendroglioma tumor tissue stained
with 655QDStAv-biotin-MAb PDGFR (tissue shown in Fig 9D).
Excitation 488 nm; emission, red, QD655 signal (655/40 nm);
yellow, autofluorescence signal (550/70 nm). Objective 20X NA
0.5, bar 25 mm.
Found at: doi:10.1371/journal.pone.0011323.s006 (0.52 MB TIF)
Figure S7 High nuclear density in QD-MAb-EGFR stained
oligodendroglioma biopsy. (A) Maximum intensity projection
through 22 mm of the oligodendroglioma biopsy after QD-MAb-
EGFR staining, fixation and counterstaining with DRAQ 5 for
DNA, excitation 633, emission .650 blue; 655QDStAv-biotin-
MAb528EGFR,excitation 488, emission .585 red. Objective 20X
NA 0.5. Field 153 mm, bar 25 mm. (B) Volume rendering (Image J
plugin Volume View) of another field of the same tissue showing
penetration of the targeted QD-probe up to 3 cell layers. The
intensities for the Draq5 staining were enhanced in the deeper
layers by 25% to compensate for fluorescence loss due to scattering
in order to make the nuclei visible in this reconstruction. Field
153 mm xy, total depth 36 mm, QD signal visible to a depth of
28 mm.
Found at: doi:10.1371/journal.pone.0011323.s007 (1.47 MB TIF)
Figure S8 Experimental scheme. Schematic depicting resection
locations and ex vivo targeted QD staining of glioma biopsy tissues
as performed in this study (A and B).
Found at: doi:10.1371/journal.pone.0011323.s008 (0.32 MB
TIF)
Movie S1 Orthotopic U87 glioma tissue from mouse brain.
Found at: doi:10.1371/journal.pone.0011323.s009 (0.69 MB
MOV)
Figure 10. QD-MAb EGFR staining of an oligodendroglioma
biopsy. Image of a Z projection, opacity 15%, ramp 40%,of 50 5-mm
sections of the oligodendroglioma biopsy shown in Fig. 9C. 655QDStAv-
biotin-MAb528EGFR, excitation 488 nm; emission .650, red, autofluo-
rescence emission 530/20, green. Objective 10X NA 0.3. Field 921 mm,
bar 100 mm.
doi:10.1371/journal.pone.0011323.g010
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QD-MAb-EGFR stained human GBM Y tissue specimen.
Found at: doi:10.1371/journal.pone.0011323.s010 (0.79 MB
MOV)
Movie S3 Confocal laser scanning 3-D reconstruction image of
QD-MAb-EGFR stained human brain tissue specimen.
Found at: doi:10.1371/journal.pone.0011323.s011 (0.65 MB
MOV)
Movie S4 Confocal laser scanning 3D reconstruction image of
GBM X stained with QD-EGF.
Found at: doi:10.1371/journal.pone.0011323.s012 (0.91 MB
MOV)
Movie S5 Confocal laser scanning 3D reconstruction image of
an astrocytoma III stained with QD-MAb-EGFR.
Found at: doi:10.1371/journal.pone.0011323.s013 (0.66 MB
MOV)
Movie S6 Confocal laser scanning 3D reconstruction image of
an oligodendoglioma stained with QD-MAb-EGFR.
Found at: doi:10.1371/journal.pone.0011323.s014 (1.40 MB
MOV)
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